Analysts/Institutional Investor Meet/Con. Call Updates

Vima Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051,Telangana, India T: +914027264141 Driven byQuality. Inspired by Science. F : +91 4027263657 VLL\SE\037\2026-2 Date: 24.07.2026 B S E Limited, National Stock Exchange ofIndia Limited, P Towers, Dalal Street, “Exchange Plaza”, Bandra, Kurla Complex, Mumbai 400001. Bandra (E), Mumbai —400051. Scrip Code: 524394 Trading Symbol: VIMTALABS Dear Sir/Madam, Sub: Transcript ofthe FY/Q1-2026-27 Earnings/Investor Call held on July 2026: 20ih Ref: Regulation 30 ofthe SEBI (LODR) Regulations, 2015. Please find enclosed herewith the transcript of“QI FY’27 Earnings Conference Call” held on Monday, 20”July 2026. Further, pursuantto Regulation 46 ofthe SEBI (ListingObligations andDisclosure Requirements) Regulations, 2015, the aforesaid information is also available on the website ofthe Company i.e., hans:!/vimta.com/invcstor-earnings-call/ This is foryour information and records. Thankingyou, ForVIMTA LABS LIMITED Sujani Vasireddi Company Secretazy and Compliance Officer End: as above. Plot No. 5, LifeSciences Facility, Neovantage Science&Technology Park Private Limited, Shamirpet GenomeValley, Turkapally Medchal-Malkajgiri, Hycferabad-500101, Telangana, India. T: +91 4067404040 E: mdoffice@vimta.com URL : www.vimta.com ClN: L24110T01990PLC011977 “Vimta Labs Limited Q1 FY '27 Earnings Conference Call” July 20, 2026 MANAGEMENT: MS. HARITA VASIREDDI – MANAGING DIRECTOR MR. SATYA SREENIVAS NEERUKONDA – EXECUTIVE DIRECTOR MR. SIVA RAMA KRISHNA – CHIEF FINANCIAL OFFICER MS. SUJANI VASIREDDI – COMPANY SECRETARY MODERATOR: MR. VISHAL MANCHANDA – SYSTEMATIX INSTITUTIONAL EQUITIES Page 1 of 16 Vimta Labs Limited July 20, 2026 Moderator: Ladies and gentlemen, good day and welcome to Vimta Labs Limited Q1 FY '27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Vishal Manchanda from Systematix. Thank you and over to you, sir. Vishal Manchanda: On behalf of Systematic Institutional Equities, I welcome you to the Q1 FY '27 earnings call of Vimta Labs. We thank the Vimta management for giving us an opportunity to host the call. We have with us the senior management of the company represented by Ms. Harita Vasireddi, Managing Director; Mr. Satya Sreenivas Neerukonda, Executive Director; Mr. Siva Rama Krishna, Chief Financial Officer; and Ms. Sujani Vasireddi, Company Secretary. I'll now hand over the call to the company management for opening remarks. Siva Rama Krishna: Thank you, Vishal. Good afternoon, everyone, and a warm welcome to our Q1 FY '27 earnings call of Vimta Labs Limited. Please note that the investor presentation and the financial results are available on the company's website and stock exchanges. Also, anything said on this call which reflects our outlook for the future or which could be construed as a forward-looking statement must be reviewed in conjunction with the risks that the company faces. This conference call is being recorded and the transcript along with the audio of the same will be made available on the website of the company as well as on the stock exchanges. Please also note that the audio of the conference call is the copyright material of Vimta Labs Limited and cannot be copied, rebroadcasted, or attributed in the press or media without specific and written consent of the company. From the management, we have with us Ms. Harita Vasireddi, Managing Director; Mr. Satya Sreenivas Neerukonda, Executive Director; Mr. Siva Rama Krishna, myself, CFO; Ms. Sujani Vasireddi, Company Secretary. Now, I request Ms. Harita Vasireddi, Managing Director of Vimta Labs Limited, to provide you with the updates for the quarter ended 30th June '26. Thank you and over to you, ma'am. Harita Vasireddi: Thank you, Shiva. Good evening, everyone. Thank you for joining us today. I am pleased to report that Vimta delivered a resilient and steady performance in the first quarter of FY '27. Total income stood at INR1,129 million, representing year-on-year growth of 13.7%. This is despite a mixed demand environment across certain services. While revenues remained broadly stable on a sequential basis, the quarter reaffirmed the strength, diversity, and adaptability of our service portfolio, enabling us to navigate the near-term headwinds while sustaining healthy profitability. Our pharma contact research and testing services delivered a consistent performance during the quarter. Revenue remained broadly stable on a quarter-on-quarter basis. However, the divisions recorded strong year-on-year growth supported by improved enquiry inflow and sustained customer engagement. Our clinical research operations, which faced challenges in the previous fiscal year, have begun to show encouraging signs of recovery with healthy enquiries and orders Page 2 of 16 Vimta Labs Limited July 20, 2026 inflows during the quarter. This provides a positive foundation for improved performance in the coming quarters. Further, the environment division has been integrated with the food division given its relative scale within the overall revenue mix to enable more efficient management and operational alignment. Consequently, the environment business will no longer be discussed as a separate division going forward. The food testing business witnessed a decline in import and export related sample receipts, primarily due to ongoing global challenges. The business has responded proactively by sharpening its focus on domestic market, thereby mitigating the impact to a certain extent. The electronics and electrical testing business remained stable during the quarter with the manpower related challenges faced earlier now addressed. With intensified market outreach, we are encouraged by the opportunities emerging in this market. India's continued emphasis on electronics manufacturing, quality certification, defence indigenization, and infrastructure development creates a favourable long-term environment for testing and certification services. In addition, the 15.19% year-on-year increase in India's FY '26-'27 defense budget allocation is expected to support higher demand for testing and qualification services for defense electronics and related systems, further strengthening the growth outlook for our Electronics and Electrical Testing business. On the demand front, enquiry levels continued to improve across both domestic and international markets. We are also witnessing an increase in the size and complexity of opportunities under evaluation, reflecting Vimta's growing relevance among customers and the increasing preference for specialized testing and research partners. Utilization levels remained healthy across major service areas. The infrastructure we have built over the years continues to be deployed effectively, while our disciplined approach to capacity addition supports optimal capital efficiency and sustainable growth. A milestone during the quarter was the progress achieved in our Biologics initiative. We successfully secured our first order for Biologics services and operationalized the facility, marking an important step in expanding our capabilities in high-growth Life Sciences segment. From a profitability standpoint, operating margins moderated on a quarter-on-quarter basis, in line with expectations, largely due to higher facility-related expenses, the impact of new labor laws and appreciation of the rupee. Despite these factors, margins improved on a year-on-year basis and our EBITDA margins continue to remain significantly above industry benchmarks. This reflects the structural strength of our business model, the depth of our operating discipline and [Showing first 8,000 characters — download PDF for full document]